FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Pfizer | Prevnar-13
Syndicate content

Pfizer seeks $1.5B adult market for Prevnar 13

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

Pfizer has high hopes for Prevnar-13, the vaccine it acquired in its buyout of Wyeth. An FDA panel has already voted in favor of the updated vaccine, and the company is awaiting final approval of the shot for infants and children.

But Martin Mackay, president of of PharmaTherapeutics at Pfizer, predicts that the company's plans for Prevnar-13 won't end there. The pharma giant plans to ask the FDA this year to approve the vaccine for adults older than 50. Approval for that population alone could account for $1.5 billion in sales, and Prevnar-13's annual sales could peak at a whopping $4.5 billion.

- check out the Reuters article

Related Articles:
FDA panel says yes to updated Prevnar
Wyeth seeks FDA approval to market Prevnar 13
Wyeth seeking regulatory approval for Prevnar-13


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about Pfizer   Prevnar-13